Avner Schneur led a number of companies from early stage to IPO or other exits.
Avner Schneur is holding President and CEO positions in the following companies:
1. President and CEO of GRM Document Management www.grmdocumentmanagement.com Under Schneur leadership GRM accelerated its growth, expended to the Digital area and geographically to South America.
2. CEO of VisualVault www.visualvault.com a leading ECM and CSP provider.
3. Schneur is also the Founder and CEO of Kormeli, LLC www.kormeli.com an investment Group dedicated to funding and guiding early-stage technology entrepreneurs and enterprises.
Schneur is the Chairman of InfinitMD www.InfinitMD.com Petpace www.Petpace.com, FoodieBytes www.foodiebytes.com Zappix www.Zappix.com and Board member in Nipendo www.nipendo.com,
Schneur is member of the Technion Industrial Engineering Faculty Advisory Board.
In late 1999 Schneur founded Emptoris Inc, leading Supply and Contract mgt Software Company and served as the company’s Chairman, President and CEO. ֵSchneur’s goal was to transform the way companies procure goods and services utilizing mathematical optimization technology. The company’s novel approach involved taking a broader look at the total cost of major procurements, ultimately enabling substantial savings for customers. Emptoris was acquired by IBM in 2011. Prior to founding Emptoris Schneur was holding number of executive positions at Vectis Corporation, a leading software vendor of electronic medical records. Astea International, a leading developer of customer interaction software, Schneur helped lead the company to a successful IPO. Elscint, Inc., a manufacturer of high-end medical imaging systems.
Schneur Graduated Cum Laude in Industrial Engineering, with a specialty in Information Systems, from the Technion (Israel Institute of Technology).
Schneur and his wife Rina established the The Rina and Avner Schneur Center of Type II Diabetes Research The center brings together top researchers from the faculty of Biomedical engineering and the faculty of Medicine at the Technion Israel Institute of Technology to seek for a cure to type II diabetes.